Evidence map›Paper›PMID 33969946›Full record

ArticleJournal of epidemiology and global health2021

Retrospective Study of Bone-TB in Oman: 2002-2019.

Wael A H Hegazy, R Al Mamari, K Almazroui, A Al Habsi, A Kamona, H AlHarthi, Areej I Al Lawati, AlZahra H AlHusaini

Open access · goldAbstract read
In one paragraph

Article in Journal of epidemiology and global health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Drug resistantPeerJ · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Wael A H HegazyDepartment of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.ORCID 0000-0001-5683-4803
R Al MamariDepartment of Pharmacy Practice and pharmaceutical sciences, Pharmacy Program, Oman College of Health Sciences, Muscat, Sultanate of Oman.
K AlmazrouiPharmacy and Medical Store Department, Clinical Pharmacy Section, Directorate General of Khoula Hospital, Muscat, Sultanate of Oman.
A Al HabsiPharmacy and Medical Store Department, Clinical Pharmacy Section, Directorate General of Khoula Hospital, Muscat, Sultanate of Oman.
A KamonaDepartment of Pharmacy Practice and pharmaceutical sciences, Pharmacy Program, Oman College of Health Sciences, Muscat, Sultanate of Oman.
H AlHarthiPharmacy and Medical Store Department, Clinical Pharmacy Section, Directorate General of Khoula Hospital, Muscat, Sultanate of Oman.
Areej I Al LawatiPharmacy and Medical Store Department, Directorate General of Royal Hospital, Muscat, Sultanate of Oman.
AlZahra H AlHusainiDirectorate of Drug Store, Injection Section, Directorate General of Medical Supplies, Muscat, Sultanate of Oman.
Zagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveLittle information is available about the etiology, pathophysiology, risk factors, and epidemiologic features of Bone Tuberculosis (Bone-TB). In this work, we present the epidemiological data about the Bone-TB in the Sultanate of Oman.

methodsRetrospectively, we identified and assessed those patients who were diagnosed with Bone-TB between January 2002 and December 2019 at Khoula Hospital. The following data were collected: demographics, clinical presentation, anatomical location, diagnosis, and treatment of the Bone-TB.

resultsDuring the study period, 115 cases of Bone-TB were diagnosed. Males were affected more than females (57.4% and 42.6%, respectively). About 30% of Bone-TB cases were primary diagnosed in other organs particularly the lungs and then after disseminated to the bone. However, the Bone-TB was detected in hip, leg, hand, shoulder, and skull bones, the most detected Bone-TB was in spine (66% of cases). After vaccination the Bacillus Calmette-Guérin (BCG) strains were identified in the bones of eight babies. Tubercle bacilli were detected by Acid-Fast Stain (AFS) in 59% of cases, and the rest of cases were confirmed using polymerase chain reaction (PCR) tests. There are two used treatment regimens, with 12.4% relapse. The gastrointestinal tract (GIT) disturbances were the most related side effects. The resistance has been detected to pyrazinamide in six cases, rifampicin in three cases, and isoniazid, streptomycin and kanamycin were detected in one case.

conclusionThe most predominant Bone-TB cases were spine-TB that were mainly disseminated from the lungs. AFS failed to detect tubercle bacilli in 40% of cases. There is no statistical significance in relapse between the used two regimens. The death was predominant among skull-TB cases.

Indexed as

Tuberculosis, OsteoarticularAdultAgedFemaleHospitalsHumansMaleMiddle AgedOmanRetrospective StudiesBone-TBextra-pulmonary tuberculosisOmanTuberculosis

Identifiers

PMID33969946
PMCPMC8242117
OpenAlexW3159084067

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.